Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Here's Why You Should Hold on to Wright Medical (WMGI) Stock
by Zacks Equity Research
Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.
Illumina (ILMN) Gains on Product Pipeline, Global Footprint
by Zacks Equity Research
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
Medtronic's MiniMed 670G Shows Favorable Outcome in Europe
by Zacks Equity Research
Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind
by Zacks Equity Research
Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.
PRA Health Simplifies Treatment Decisions With Metys Launch
by Zacks Equity Research
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
Here's Why You Should Retain Pacific Biosciences For Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.
3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.
Intersect ENT Rides on Innovation Amid Pricing Concerns
by Zacks Equity Research
The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.
HMS Holdings Acquires VitreosHealth, Boosts PHM Solution Set
by Zacks Equity Research
HMS Holdings (HMSY) can leverage VitreosHealth's prescriptive health insights that will enhance its growing and lucrative PHM suite.
Here's Why You Should Retain OPKO Health (OPK) Stock For Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.
Medtronic Collaborates With Novo Nordisk for Diabetes Care
by Zacks Equity Research
This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.
Add These 5 Stocks With Impressive Interest Coverage Ratio
by Sumit Singh
Interest coverage ratio is used to determine how effectively a company can pay the interest charged on its debt.
DVA vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. AMED: Which Stock Is the Better Value Option?
BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal
by Zacks Equity Research
This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.
Bruker (BRKR) Introduces the nanoIR3-s Broadband System
by Zacks Equity Research
The launch of the FTIR spectroscopy system complements Bruker's (BRKR) target to boost its portfolio of nanoIR products.
Integra Buys Rebound Therapeutics to Boost Neurosurgery Line
by Zacks Equity Research
Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.
Medtronic's (MDT) MiniMed 670G Gains German Reimbursement
by Zacks Equity Research
Medtronic's (MDT) MiniMed 670G is witnessing a solid uptake in the United States ever since its launch last year.
Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well
by Zacks Equity Research
The results of the study will prove to be a major stride for Medtronic (MDT) to treat patient suffering from renal diseases.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.
Masimo (MASI) Boosts O3 Platform With Three New Indices
by Zacks Equity Research
Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.
Here's Why You Should Retain NextGen Healthcare Stock Now
by Zacks Equity Research
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Here's Why You Should Invest in Amedisys (AMED) Right Now
by Zacks Equity Research
Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.
Here's Why You Should Invest in Integer Holdings (ITGR) Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.